Palatin Technologies, Inc. (PTN)
NYSEAMERICAN: PTN · Real-Time Price · USD
0.2047
-0.0049 (-2.34%)
At close: Apr 25, 2025, 4:00 PM
0.2006
-0.0041 (-2.00%)
After-hours: Apr 25, 2025, 7:43 PM EDT
Palatin Technologies Employees
Palatin Technologies had 30 employees as of June 30, 2024. The number of employees decreased by 4 or -11.76% compared to the previous year.
Employees
30
Change (1Y)
-4
Growth (1Y)
-11.76%
Revenue / Employee
$11,667
Profits / Employee
-$898,407
Market Cap
5.38M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PTN News
- 10 days ago - Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide - PRNewsWire
- 13 days ago - Palatin Appeals NYSE American Notice of Delisting - PRNewsWire
- 17 days ago - NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN) - Business Wire
- 17 days ago - Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal - PRNewsWire
- 17 days ago - Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting - PRNewsWire
- 27 days ago - Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study - PRNewsWire
- 4 weeks ago - Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177 - PRNewsWire
- 4 weeks ago - Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency - PRNewsWire